Abstract:A literature review was conducted to elucidate the respective reproductive safety profiles of different SSRIs to inform the prescribing practices of doctors treating pregnant women with anxiety and depression. Background: Women are most likely to be diagnosed with depression or anxiety between the ages of 25 and 44 years, which are also the years of childbearing potential (Burke et al., 1991). Therefore a substantial number of women face a decision about whether or not to take an antidepressant or anxiolytic during pregnancy. There are no psychotropic medications that have UK marketing authorisation (NICE, 2014), no clear clinical consensus has been reached regarding the use of SSRIs in pregnancy, and clinicians lack a resource which discusses the reproductive safety profiles of different SSRIs rather than the class of drugs as a whole. Subjects and methods: We performed a search for the English language literature indexed on MEDLINE/PubMed for the period 2012 to 2017, using the following key terms: fluoxetine, prozac, paxil, oxactin, paroxetine, seroxat, sertraline, lustral, citalopram, cipramil, escitalopram, cipralex, fluvoxamine, faverin, with 'pregnant woman', 'pregnant women', pregnancy. We excluded general SSRI and pregnancy articles (although we did read these papers for valuable background information) because we are interested in elucidating the differences between the drugs in this class, rather than the general effects of the SRRI class as a whole. Results: The literature shows that paroxetine and fluoxetine have the strongest association with negative outcomes (significant malformations, PPHN and PNAS) whilst the associations between sertraline and citalopram with negative outcomes remains mixed and generally unsubstantiated when studies that show an association are controlled for the effects of maternal depression and associated factors. There are too few studies to draw definite conclusions regarding the safety of escitalopram and fluvoxamine. Conclusions: Sertraline and citalopram should be first-line drug treatments for anxiety and depression in pregnant women in the SSRI class. Sertraline can be continued in breast-feeding as the concentration found in breast milk is very low and has not been linked to infant complications. Furthermore, it would be useful to assess GPs current knowledge and confidence levels about prescribing, to see whether further education is needed in this area to encourage an open discussion of the risks and benefits of medication or no medication. It would also be useful to conduct further research on escitalopram which is likely to grow in popularity in the coming years as it came off patent in 2012. When these holes are filled, a clinical protocol for treating anxiety and depression in pregnant women should be created and implemented for the UK population.

A Critical Retrospective Study

Use of selective serotonin reuptake inhibitors reduces fertility in men

The Effect of SSRIs on Semen Quality: A Systematic Review and Meta-Analysis

In vitro effects of antidepressants on human sperm function

Effect of smoking on reproductive hormones and semen parameters of infertile Saudi Arabians

Paternal use of selective serotonin reuptake inhibitors and adverse health outcomes: A nationwide cohort study on 13,547 exposed children

A Cross-Sectional Study of Mental Illnesses Among Infertile Women in Saudi Arabia

A Systematic Review on the Genotoxic Effects of Selective Serotonin Reuptake Inhibitors

What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence

Effects of depression pharmacotherapy in fertility treatment on conception, birth, and neonatal health: A systematic review

Prospective study to evaluate the risk factors associated with male infertility at tertiary care centre

Effects of the selective estrogen receptor modulators for the treatment of male infertility: a systematic review and meta-analysis

Selective Serotonin Reuptake Inhibitor Use During Early Pregnancy and Congenital Malformations: a Systematic Review and Meta-Analysis of Cohort Studies of More Than 9 Million Births

Effects of selective serotonin reuptake inhibitors on endocrine system (Review)

Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose

(100) Urinary and Gynecologic Adverse Events Associated with Ssri Use

Exploring women's perception and attitude towards antidepressant use: a cross-sectional study

The six most widely used selective serotonin reuptake inhibitors decrease androgens and increase estrogens in the H295R cell line

Changes in Testosterone Levels Following Surgical Sperm Retrieval in Men with Non-Obstructive Azoospermia: Systematic Review and Meta-Analysis

Psychological struggles in tunisian Infertile couples: A gender Perspective